NEW NMN SUPPLEMENT ELEVANT POWERS IMMUNITY AND BRINGS NEW LEVELS OF SAFETY AND TRANSPARENCY FOR CONSUMERS
Elevant, a new brand with deep experience in cellular metabolism science, is bringing a clinically tested super nutrient with new levels of scientific rigor, quality, and safety to the cellular optimization market.
New York, February 2021 – Elevant, an American health and wellness brand that develops cellular health solutions with leading scientists, has released an advanced dietary supplement containing a high purity form of NMN. Elevant is part of Seneque, an international biotechnology company established in Switzerland that is redefining healthspan and longevity.
Elevant this week launched Prime capsules in the USA; clinically tested NMN supplements that work directly within cells to power immunity, deliver daily energy and fight aging. Prime’s launch follows compelling safety endorsements in the form of Self-GRAS affirmation and highly favorable results from a world-first OECD 408 toxicology study.
With the launch of its maiden product, Elevant brings a rigorous scientific approach and standards of research used in the pharmaceutical industry to the supplement market, where clarity on provenance and purity can often be hard to find for consumers. Elevant controls every step Prime takes – from ingredient sourcing, a proprietary production process in Europe, to distribution – to ensure those seeking to boost health and immunity can access a high purity NMN supplement created under strict quality and manufacturing standards.
Elevant Prime NMN Capsules were developed based on findings from pioneering cellular metabolism research which showed the ability of NMN to function as an NAD+ booster. Taking Prime first thing in the morning and again in the early afternoon works in harmony with the body’s natural NAD+ cycles to spark cellular energy that supports effective immune response and daily energy.
Elevant’s high-purity form of NMN, called NMN-C®, acquired Self-GRAS (Generally Recognized as Safe) status in accordance with stringent US FDA regulatory guidelines in November 2020. The Self-GRAS review was performed by an independent panel of toxicology and nutrition experts, which rigorously evaluated research studies and toxicology data on Elevant NMN-C® and concluded that it is not harmful under its intended conditions of use (UL of 2.2mg/pound for humans, i.e., 300mg for a 135 pounds adult).
“Self-GRAS status is a major endorsement of the quality and safety of our NMN”, says Elevant Chief Scientist Dr. Alessia Grozio, a biochemist who helped discover a groundbreaking NMN transporter that delivers NMN directly into cells1.
« Transparency and scientific rigor are at the heart of everything Elevant does”, says Dr. Eric Verdin, President of the Buck Institute for Research on Aging and Chair of the Elevant Scientific Advisory Board.
Transparency for consumers
Consumers received further transparency in early 2021, with the publication of the results of a recent OECD 408 toxicology study on Elevant’s NMN-C®. The study – the first of its kind to be undertaken on NMN – analyzed the No Observable Adverse Effect Level (NOAEL), with results showing NMN-C® to be an extremely well-tolerated option in comparison to other popular NAD+ boosters.
Elevant is exploring the health benefits of NMN through pre-clinical research partnerships with leading institutes in Europe and America, such as the Buck Institute for Research on Aging; a collective of the world’s top scientists in the field of cellular metabolism and aging.
Elevant’s scientifically rigorous approach is grounded in the most extensive clinical research program to analyze the health benefits of NMN in humans to date. This first-of-kind research will propel further development of NMN-C® to support cardiovascular, cognitive, muscular, skin, and immune health.
“For thousands of years the human body has been creating NMN to fuel cells and keep us healthy”, says Dr. Grozio. “With Elevant Prime we have taken the best of nature’s design and modern science to help people unlock a multitude of potential health benefits as a result of boosting NAD+”.
• Elevant Prime is available now from elevant.co.
• Annual subscriptions available
Throughout 2021 Seneque’s portfolio of science-based consumer brands will roll out an extensive pipeline of NMN-based products that support a broad spectrum of health, energy, skincare and anti-aging needs.
Elevant is an American brand that is transforming advances in cellular longevity research into effective daily solutions which support immunity, health, energy and lifespan.
Elevant is part of Seneque – an international biotechnology company established in Switzerland.
Together with Seneque, Elevant is developing health solutions proven through in-human clinical trials. This joint research is advancing the body of knowledge around NMN to discover new and better ways to help people harness their cellular health and energy.
Elevant’s Scientific Advisory Board is led by two recognized NAD+ experts – Dr. Eric Verdin, President of the Buck Institute for Research on Aging, and Dr. Alessia Grozio, a biochemist who co-discovered a groundbreaking transporter that delivers NMN directly into cells.
Find out more at elevant.co
Based in Switzerland, Seneque’s team of international biochemists, cellular senescence scientists, professors, and other experts is breaking new ground with its research into cellular metabolism and longevity.
Seneque was founded in 2018 by French entrepreneur Guillaume Bermond. Passionate about biology, he assembled a team of cellular longevity pioneers to pursue his vision of a world where everyone has the health, energy, and time to live life as richly as they aspire.
The name ‘Seneque’ comes from Seneca the Younger, a Roman philosopher who encouraged people to discover vitality using their inner resources – something Seneque is enabling today using modern technology to activate natural processes within the body that help people live longer, healthier lives.
Phone : +41 (0)79 393 42 66
1. Grozio, A., Mills, K.F., Yoshino, J. et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab 1, 47–57 (2019). https://doi.org/10.1038/s42255-018-0009-4